News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
581,962 Results
Type
Article (19197)
Company Profile (166)
Press Release (562596)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (198525)
Career Advice (703)
Deals (30770)
Drug Delivery (90)
Drug Development (65743)
Employer Resources (54)
FDA (12428)
Job Trends (11108)
News (288117)
Policy (24180)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (830)
Accelerated approval (44)
ADA (26)
Adcomms (10)
Allergies (143)
Alliances (41852)
ALS (148)
Alzheimer's disease (1274)
Antibody-drug conjugate (ADC) (350)
Approvals (13058)
Artificial intelligence (511)
ASCO (219)
Autoimmune disease (253)
Automation (40)
Bankruptcy (320)
Best Places to Work (8378)
BIO (47)
BIOSECURE Act (10)
Biosimilars (191)
BioSpace Insights (77)
Biotechnology (102)
Bladder cancer (155)
Brain cancer (56)
Breast cancer (605)
Cancer (4493)
Cardiovascular disease (360)
Career advice (608)
Career pathing (15)
CAR-T (219)
CDC (8)
Celiac Disease (1)
Cell therapy (612)
Cervical cancer (41)
Clinical research (58939)
Collaboration (1735)
Commercialization (4)
Company closure (2)
Compensation (1492)
Complete response letters (61)
COVID-19 (1288)
CRISPR (82)
C-suite (1061)
Cystic fibrosis (126)
Data (6650)
Decentralized trials (1)
Denatured (23)
Depression (125)
Dermatology (68)
Diabetes (443)
Diagnostics (4845)
Digital health (45)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (271)
Drug pricing (126)
Drug shortages (15)
Duchenne muscular dystrophy (230)
Earnings (81419)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99308)
Executive appointments (967)
FDA (15597)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (20)
Frontotemporal dementia (29)
Funding (1238)
Gene editing (165)
Generative AI (35)
Gene therapy (468)
GLP-1 (678)
Government (2020)
Grass and pollen (5)
Guidances (332)
Healthcare (11056)
Hematology (128)
HIV (55)
Huntington's disease (32)
IgA nephropathy (101)
Immunology and inflammation (168)
Immuno-oncology (76)
Indications (196)
Infectious disease (1521)
Inflammatory bowel disease (173)
Inflation Reduction Act (9)
Influenza (97)
Intellectual property (297)
Interviews (94)
IPO (13984)
IRA (33)
Job creations (3104)
Job search strategy (550)
JPM (30)
Kidney cancer (20)
Labor market (39)
Layoffs (254)
Leadership (11)
Legal (6588)
Licensing (8)
Liver cancer (55)
Longevity (25)
Lung cancer (638)
Lymphoma (344)
Machine learning (37)
Management (18)
Manufacturing (922)
Marketing (12)
MASH (164)
Medical affairs (1)
Medical device (9296)
Medtech (9447)
Mergers & acquisitions (17961)
Metabolic disorders (1069)
mRNA (111)
Multiple sclerosis (139)
NASH (15)
Neurodegenerative disease (303)
Neuropsychiatric disorders (71)
Neuroscience (2448)
Neurotech (1)
NextGen: Class of 2026 (3909)
Non-profit (1264)
Now hiring (24)
Obesity (428)
Opinion (163)
Ovarian cancer (175)
Pain (244)
Pancreatic cancer (227)
Parkinson's disease (278)
Partnered (21)
Patents (583)
Patient recruitment (598)
Peanut (39)
People (50727)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18183)
Phase 2 (25917)
Phase 3 (19239)
Pipeline (8760)
Policy (165)
Postmarket research (2127)
Preclinical (7551)
Press Release (49)
Prostate cancer (237)
Psychedelics (31)
Radiopharmaceuticals (274)
Rare diseases (861)
Real estate (4463)
Recruiting (20)
Regulatory (19787)
Reports (28)
Research institute (965)
Resumes & cover letters (95)
Rett syndrome (42)
RNA editing (12)
RSV (54)
Schizophrenia (146)
Series A (226)
Series B (157)
Service/supplier (5)
Sickle cell disease (97)
Special edition (12)
Spinal muscular atrophy (116)
Sponsored (15)
Startups (2782)
State (2)
Stomach cancer (8)
Supply chain (96)
Tariffs (71)
The Weekly (55)
Vaccines (515)
Venture capital (56)
Weight loss (228)
Women's health (101)
Worklife (4)
Date
Today (58)
Last 7 days (369)
Last 30 days (2015)
Last 365 days (23164)
2026 (14964)
2025 (23324)
2024 (27291)
2023 (31435)
2022 (40795)
2021 (43395)
2020 (39883)
2019 (29720)
2018 (22661)
2017 (24723)
2016 (23559)
2015 (29449)
2014 (25680)
2013 (22089)
2012 (24115)
2011 (24455)
2010 (23686)
Location
Africa (468)
Alabama (81)
Alaska (2)
Arizona (333)
Arkansas (13)
Asia (30211)
Australia (4154)
California (12656)
Canada (3453)
China (1039)
Colorado (509)
Connecticut (465)
Delaware (274)
Europe (54773)
Florida (1934)
Georgia (417)
Hawaii (3)
Idaho (49)
Illinois (855)
India (99)
Indiana (554)
Iowa (16)
Japan (558)
Kansas (119)
Kentucky (36)
Louisiana (31)
Maine (28)
Maryland (1370)
Massachusetts (8690)
Michigan (325)
Minnesota (602)
Mississippi (5)
Missouri (106)
Montana (27)
Nebraska (16)
Nevada (117)
New Hampshire (68)
New Jersey (3191)
New Mexico (19)
New York (3111)
North Carolina (1523)
North Dakota (4)
Northern California (6345)
Ohio (303)
Oklahoma (17)
Oregon (29)
Pennsylvania (2402)
Puerto Rico (26)
Rhode Island (36)
South America (732)
South Carolina (79)
South Dakota (1)
Southern California (5212)
Tennessee (147)
Texas (2030)
United States (42882)
Utah (386)
Vermont (1)
Virginia (270)
Washington D.C. (51)
Washington State (985)
West Virginia (2)
Wisconsin (108)
Wyoming (2)
581,962 Results for "ionis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.
June 25, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.
July 22, 2026
·
2 min read
·
Heather McKenzie
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM.
July 10, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.
July 10, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
July 29, 2026
·
5 min read
Press Releases
Ionis to hold second quarter 2026 financial results webcast
July 16, 2026
·
1 min read
Press Releases
Ionis reports second quarter 2026 financial results and highlights progress on key programs
July 29, 2026
·
17 min read
Rare diseases
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.
February 18, 2026
·
3 min read
·
Annalee Armstrong
Cardiovascular disease
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.
July 9, 2026
·
3 min read
·
Tristan Manalac
Press Releases
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
July 13, 2026
·
5 min read
1 of 58,197
Next
